Skip to main content
Fig. 1 | Trials

Fig. 1

From: The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial

Fig. 1

Patient disposition chart showing study participation. Of randomized patients, 70 patients will be included in the control group as the continuous administration, and the other 70 patients in the intervention group as the other day administration after 8 weeks every day of relugolix. PS, performance status

Back to article page

Trials

ISSN: 1745-6215